Blueprint Medicines Corp: directors' dealings · United States · SEC (Form 4)

About Blueprint Medicines Corp

Blueprint Medicines Corp. is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. The company focuses on discovering, developing, and commercializing precision medicines for serious diseases, with a strategic emphasis on allergy/inflammation and oncology/hematology. Founded in 2011 by scientists with deep expertise in kinase biology and translational medicine, Blueprint Medicines was built around a core idea: address the underlying biology of disease rather than just the symptoms. Its global headquarters are in Cambridge, Massachusetts, placing it in one of the strongest biotech clusters in the country. The company’s business model combines commercial-stage assets with a development pipeline. Blueprint Medicines has two approved medicines and a portfolio of investigational programs. Its flagship marketed product is AYVAKIT/AYVAKYT (avapritinib), a targeted therapy used in certain mast cell disorders, including systemic mastocytosis, and in specific forms of gastrointestinal stromal tumor with defined mutations. In recent years, the company has also evolved its scientific platform beyond kinase inhibitors into additional modalities, including targeted protein degradation, while adding advanced translational capabilities and artificial intelligence / machine learning tools to support discovery productivity. From a competitive standpoint, Blueprint Medicines occupies a differentiated position in rare disease and precision oncology. Its value proposition rests on biologic selectivity, clinical differentiation, and the ability to build a durable commercial franchise in narrowly defined patient populations with high unmet medical need. That makes the company potentially attractive to investors seeking exposure to specialty pharma and precision medicine, but it also means the stock can be sensitive to clinical readouts, regulatory developments, and concentration risk across a limited number of products and indications. Geographically, Blueprint Medicines has built a footprint beyond the U.S. and has marketed products in Europe in approved indications. The company’s current public messaging highlights programs in mast cell disorders, including systemic mastocytosis and chronic urticaria, as well as oncology opportunities in breast cancer and other solid tumors. This broader pipeline suggests a strategy of extending its core expertise in mast cell and cancer biology into adjacent therapeutic opportunities. Recent corporate developments have been important. On February 28, 2026, Blueprint Medicines announced four-year PIONEER data showing sustained benefit and long-term safety for AYVAKIT in indolent systemic mastocytosis, reinforcing the drug’s commercial and clinical relevance. In addition, SEC Form 4 filings continue to show insider transaction activity around the company, which is closely watched by market participants following U.S.-listed healthcare names. For investors in France, Belgium, and Switzerland, Blueprint Medicines is therefore a high-quality precision-medicine story on the NASDAQ in the United States, combining an established commercial asset, ongoing pipeline expansion, and a strong focus on targeted therapies for difficult-to-treat diseases.